NCT03601611View on ClinicalTrials.gov

Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms

NACompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 28, 2020

Study Completion Date

January 28, 2020

Conditions

Solid TumorColitisArthritis

Interventions

DRUG

Tocilizumab (RoACTEMRA®)

Prednisolon will be given in case of worsening of symptoms

Trial Locations (1)

2730

Herlev & Gentofte University Hospital, Denmark, Herlev

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Herlev Hospital

OTHER